HSV-2 Shedding Resolution After Acyclovir Treatment

Status Completed

Clinical Trial Summary

Clinical Trial Description

The purpose of the study is to evaluate the pattern of viral shedding after beginning treatment with acyclovir for a clinical recurrence of genital herpes and to compare it with the pattern of viral shedding during an untreated clinical recurrence of genital herpes.

Participants are asked to visit the University of Washington Virology Research Clinic for an initial screening appointment in which the clinician will ensure eligibility and informed consent will be obtained.

Participants who experience an outbreak during the next year will be asked to call the clinic at the beginning of their next outbreak. The clinician will arrange to admit the participant to the UW General Clinical Research Center (GCRC) for a 5-day hospitalization stay. During hospitalization, participants will take acyclovir (400mg 3 times daily) and genital swabs will be collected every 2 hours during the day and every 4 hours at night for 5 days. After the last swab has been taken, the study nurse at the GCRC will do a final genital exam and the participant will be discharged. Some participants will also be asked to enroll in a control arm during which the same procedures will be followed except they will not take acyclovir during the recurrence. ;

Study Design

Observational Model: Case-Only, Time Perspective: Prospective

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT00495573
Study type	Observational
Source	University of Washington
Contact
Status	Completed
Phase	N/A
Start date	June 2007
Completion date	March 2012

View Details

See also
Status	Clinical Trial	Phase
Active, not recruiting	`NCT06033261` - A Study of mRNA-1608, a Herpes Simplex Virus -2 (HSV-2) Therapeutic Candidate Vaccine, in Healthy Adults 18 to 55 Years of Age With Recurrent HSV-2 Genital Herpes	Phase 1/Phase 2
Completed	`NCT01132716` - Bioequivalency Study of Valacyclovir Hydrochloride 1000 mg Under Fed Conditions	N/A
Completed	`NCT01132729` - Bioequivalency Study of Valacyclovir Hydrochloride 1000 mg Under Fasting Conditions	N/A
Completed	`NCT00362297` - Randomized Trial to Evaluate Suppressive Effect of High-Dose Acyclovir Versus Once-Daily Valacyclovir on Persons With HSV-2	Phase 4
Completed	`NCT03831165` - Melatonin Effects on Genital Herpes in Brazilian Women	Phase 4
Terminated	`NCT01658826` - Safety and Efficacy Comparator Trial of a New Drug Against Genital Herpes	Phase 2
Completed	`NCT00262106` - Trial to Evaluate PRO 2000/5 Gels for the Prevention of Vaginally Acquired HIV Infection	Phase 3
Completed	`NCT01346475` - Randomized Trial to Evaluate Suppressive Effect of High-Dose Valacyclovir Versus Once-Daily Valacyclovir on Persons With HSV-2	Phase 4
Completed	`NCT01390805` - Special Drug Use Investigation for VALTREX (Valaciclovir) (Suppression Prophylaxis)	N/A
Terminated	`NCT03146403` - Maintenance Dose Study of GEN-003 in Subjects With Genital Herpes Infection	Phase 2
Completed	`NCT03080961` - The VIBLOK SAfety and perFormancE Trial	N/A
Completed	`NCT00306787` - Efficacy and Safety of Famciclovir 1-day Treatment Compared to 3-day Treatment With Valacyclovir in Adults With Recurrent Genital Herpes	Phase 3
Completed	`NCT00231049` - Trial Evaluating Safety, Tolerability and Immune Response of AG-707	Phase 1
Completed	`NCT00477334` - Patient-initiated Episodic Treatment of Recurrent Genital Herpes in Black Patients	Phase 4
Not yet recruiting	`NCT03595995` - A Phase 2 Trial to Evaluate the Safety and Efficacy of UB-621	Phase 2
Completed	`NCT01281007` - Efficacy of Oral Famciclovir 125mg Comparing to Aciclovir 200 mg Treatment in Patients With Active Recurrent Genital Herpes	Phase 3
Completed	`NCT01112956` - Serologic Assays for the Diagnosis of Herpes Simplex Virus Type 2	N/A
Completed	`NCT00129818` - A Study to Evaluate the Effect of Famciclovir in Reducing Herpes Virus Shedding	Phase 4
Completed	`NCT00808405` - GUD Clinical and Virologic Response to Acyclovir in HIV Negative African Women	N/A
Terminated	`NCT00495716` - Effect of HSV-2 Suppressive Therapy on Sexual Behavior	Phase 4